The world’s first anti-Covid pill has been approved in the United Kingdom very much for immediate treatment of Covid-19 patients in India, specifically for adults. The data is being reviewed by The Drugs Controller General of India. Sun Pharmaceutical Industries has stated that it is all ready to present Merck Sharp Dohme (MSD) and Ridgeback’s ‘Molnupiravir’ which would be coming under the brand name ‘Molxvir’.
Sun Pharma, which is known as one of the leading companies in India has entered into open licensing agreements with Merck.
“The recent authorization of Molnupiravir, licensed from MSD and Ridgeback, by the UK regulator is a positive step. In line with our consistent efforts to accelerate access to new drugs for COVID-19 treatment, we are gearing up to make Molxvir available to patients and healthcare providers across India at an economical price post-approval by DCGI,” as stated by Kriti Ganorkar, CEO of Sun Pharma India Business.
The United States is also being stated as one of the nations who are reviewing and going through specific data of Molnupiravir.
The main question arise here is who can take this pill? The simple answer to this is that specifically adults who are facing terrible symptoms or are hospitalized due to Covid-19 are the only ones who are eligible to take this pill. Although, many experts have also stated this that one should not take this anti-Covid pills as an alternative to vaccine. The pill should only be taken within the first few days when the Covid symptoms are prominent.
Molnupiravir does not require to be kept in cold storage like most vaccines. While the Phase 3 trial was on by Merck, Molnupiravir notably decreased the risk of getting admitted in hospital or even death by almost around 50 percent in a much-planned analysis of the MOVe-OUT trial in at a bit of risk and even adult patients who are not hospitalized with slight or mild COVID-19.
Molnupiravir showed consistent efficacy among viral variants such as Gamma, Mu, and Delta based on the various participants with some available date (approx. 40 percent of participants).